A series of 4-aryl-4,7-dihydropyrazolo[3,4-b]pyridine-5-carboxylate derivatives (72-149) was prepared and the compounds were tested for Ca-blocking activity in isolated guinea pig portal vein, antihypertensive activity in spontaneously hypertensive rats, and coronary vasodilating effect in isolated guinea pig heart. A number of derivatives had potent antihypertensive and coronary vasodilating activities. The structure-activity relationships of the series indicated that a 3cyclopentyl or 3-cyclohexyl substituent and a hydrophobic 5-ester moiety with moderate bulkiness were effective for increasing the pharmacological potencies.
05,
means of the Knoevenagel reaction7) from the corresponding aldehydes (156) and alkyl acetoacetates (157), prepared by the reaction of diketene with alcohols') (Chart 3). Heating a solution of 5-amino-1 -methylpyrazole (1) with methyl 2-nitrobenzylideneacetoacetate (34) in tert-butanol afforded methyl 4,7-dihydro-1,6-dimethy1-4-(2-nitrophenyppyrazolo[3,4-b]pyridine-5-carboxylate (72) in 42.1% yield, together with a small amount of 1-methy1-5-(2nitrobenzylidene)aminopyrazole (151a).9) Similar treatment of 5-amino-3-cyclopenty1-1methylpyrazole (14) with methyl 3-nitrobenzylideneacetoacetate (58) gave the 3-cyclopenty1-4-(3-nitrophenyl) derivative (76) in 94.0% yield. The compounds listed in Tables I and II were prepared from the corresponding 5-aminopyrazoles and acetoacetate derivatives in the same manner as described for the preparation of 72. Reduction of 76 yielded the 4-(3-aminophenyl) derivative (150). Compounds 72-150 were characterized as having the 4-ary1-4,7-dihydro-6methylpyrazolo[3,4-b] pyridine structure on the basis of their proton nuclear magnetic resonance and infrared (I R) spectra, as well as carbon-13 nuclear magnetic resonance ("C-NMR) data in some cases. However, the data did not completely rule out another structure, 6-aryl-1, 2-dihydro-4-methylpyrazolo[3,4-b] pyridine form. In order to unequivocally establish the structure, the synthesis of 149 was successfully conducted via an alternative pathway starting from a known compound (158),' a) as shown in Chart 4. Further, the product (162), which had been derived from 76 via oxidation followed by hydrolysis and decarboxylation, was identical with 3-cyclopenty1-1,6-dimethy1-4-(3-nitrophenyl)pyrazolo [3,4-b] pyridine, obtained by the reaction of 14 with 3-nitrobenzoylacetone (163).m) Further confirmation of the structure came from an X-ray analysis of 76 hydrochloride") ( Fig. 1) .
Pharmacological

Results and Discussion
The Ca-blocking activity of each test compound was evaluated in terms of its inhibitory effect on the K-contracture of isolated guinea pig portal vein.12) The values of the concentration required for 50% relaxation of the contracture (RC50) by the compounds and two reference Ca-blockers, nifedipine and nicardipine hydrochloride, were calculated from Chart 4 the concentration-response curves (Table I) . Compound 72, methyl 4,7-dihydro-1,6-dimethy1-4-(3-nitrophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate, had no Ca-blocking effect, but the introduction of a 3-alkyl substituent into it increased its potency. Compounds 75-82 exhibited potent Ca-blocking activity, though they were less active than nifedipine and nicardipine hydrochloride. Similarly, the 3-phenyl and 3-isopropoxycarbonyl derivatives (84 and 87) as well as the 3-alkyl-4-(2-chlorophenyl) derivative (88) showed moderate potency. TABLE I. Alkyl (IV) 4-Ary1-1-R-3-R3-4,7-dihydro-Abbreviations used are: anti-HT activity, antihypertensive activity; SBP, systolic blood pressure; CVD effect, coronary vasodilating effect; CPF, coronary perfusion flow. a) RC50 values are the concentrations required for 50% relaxation of the contracture of isolated guinea-pig portal veins by KC1 at 5 x 10-2 M. Usually 4 to 6 preparations were used for the determination of RC50 of test compounds except in the cases of 80 and 82 (2 preparations for each). b) For the determination of antihypertensive activities, test compounds were intraperitoneally administered at a dose of 3 mg/kg in 2 SHRs. Four SHRs were used for nifedipine Replacements with 1-phenyl and 1-cyclopentyl substituents resulted in a decrease of potency as seen in compounds 85 and 83.
Antihypertensive activity was evaluated in conscious spontaneously hypertensive rats (SHR). Systolic blood pressure (SBP), recorded indirectly from the tail, was determined before dosing and at various time intervals during the ensuing 6 h after intraperitoneal administration of a test compound.") As can be seen in Table I , the compounds with potent 6-methylpyrazolo[3,4-b] pyridine- 5-carboxylates (72-89) and 76. c) The test compounds were intravascularly administered at a dose of 0.1 pg. Two to 4 preparations for each compound were used for the determination of CVD effect. The values in parentheses are the times (min) required for 50% recovery of the maximum change of CPF. d) LD,0 values were determined after the oral administration of test compounds to 12 to 40 male slc. ddY mice. However, small number of mice was employed in some cases to obtain a rough indication of toxicity: 77, 93, 116, 117, 119, 123 and 131. e ) Not tested. f) Hydrochloride. Ca-blocking activity showed a marked antihypertensive effect. Maximal decreases in SBP for compounds 76, 79, 81 and 82 observed at 1-2 h post administration were greater than those caused by nifedipine.
Coronary vasodilating activity was measured in isolated guinea pig heart by Langendorff's method.") The values shown in Table I were obtained by measuring the volume of the coronary arterial perfusates after intracoronary administration of the test compounds. Increases in coronary arterial flow were induced by the 4-(3-nitrophenyl) derivatives (76 and 81), in accordance with their Ca-blocking and antihypertensive activities, and the durations of action of these compounds were longer than those of the reference drugs. On the other hand, the 4-(2-nitrophenyl) derivatives (79 and 82), which showed stronger antihypertensive activity than 76 and nifedipine, did not exhibit a coronary vasodilating effect. Potent effects were observed with 80, a 5-(2-methoxy)ethoxycarbonyl analogue of 79, and also with the 4-(2-chlorophenyl) derivative (88), which had only weak potency for lowering SBP.
On the basis of these findings on the structure-activity relationships, pyrazolo[3,4b]pyridines were further modified to improve the pharmacological effects. First, 3-alkyl and 3aryl substituents were introduced into compound 72. Table II lists a series of methyl 3substituted-4,7-dihydro-1,6-dimethy1-4-(2-or 3-nitrophenyl)pyrazolo[3,4-b]pyridine- 5-carboxylates (90-112) and their antihypertensive and coronary vasodilating activities. Compounds 90, 96, 99 and 101, which have 3-isobutyl, 3-cyclobutyl, 3-cyclopentenyl and 3- cyclohexenyl substituents, respectively, showed relatively potent antihypertensive activity. The 3-cyclopentylmethyl derivative (93) showed potent coronary vasodilating activity, comparable to that of nifedipine, but its antihypertensive effect was weak. The second modification focused on the 5-ester group in 76, 79 and 82, which showed potent Ca-blocking and antihypertensive activities. Table II lists a series of 3 (113 139) having various 5-ester substituents and their biological activities. Most of these compounds exhibited potent antihypertensive and coronary vasodilating activities with long-lasting actions. Compounds 117-124, which had phenethyloxycarbonyl or substituted phenethyloxycarbonyl substituents at the C-5 position, showed remarkably strong potencies with long durations of action. Some 5-aryloxyethyl esters (126-128), as well as 5-isopropoxyand 5-cyclopentyloxyethyl esters (129 and 130) also showed strong potencies. On the other hand, 125, which had a bulkier cyclohexyloxycarbonyl group at the C-5 position, showed lesser potency. Table II also includes compounds having other substituents at the C-3 and C-4 positions of the 4,7-dihydropyrazolo[3,4-b]pyridine system and their pharmacological activities. Compound 143 showed good potency, comparable to the reference compounds. However, compounds 144-148 and 150, which had other substituents in place of the 2-or 3-nitrophenyl groups at the C-4 position, showed lesser potencies, probably because of their chemical instability.
Although a precise relationship can not yet be established between chemical structure (continued) and biological activity, fusion of the pyrazole nucleus to 1,4-dihydropyridine seems to satisfy the structure requirements for enhancing the Ca-blocking activity. The results also indicate that the potency is enhancedin those compounds which have a 3-cycloalkyl substituent and a hydrophobic 5-ester moiety with moderate bulkiness. The nitro group on the 4-phenyl substituent seems to be necessary not only to increase the pharmacological activities but also to increase the stability of the compounds. Finally, the acute toxicity in mice was determined for several compounds which showed potent antihypertensive and coronary vasodilating activities. The L1350 values were calculated by the Bliss method') for the 24 h after oral administration (Tables I and II) .
On the basis of these results, five compounds (76, 117, 129, 130 and 143) , which showed potent antihypertensive and coronary vasodilating actions and were less toxic in mice, were selected as promising agents. Further pharmacological evaluations of these compounds are in progress.
Experimental
All melting points and boiling points are uncorrected. IR spectra were measured on a Hitachi 260-10 spectrometer. 1H-NMR spectra were recorded with a Varian EM390 spectrometer in the indicated solvents. Chemical shifts are represented by 6-values using tetramethylsilane as an internal standard and the abbreviations of signal patterns are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad. Mass spectra (MS) were obtained on an RMU-8GN mass spectrometer. After the reactions were run as indicated, thin-layer chromatography (TLC) was conducted on Merck Silica gel F254 plates. Standard work-up procedures were as follows: the reaction mixture was partitioned between the indicated solvent and water, and the organic extract was washed successively with water, NaHCO3 solution (aq. NaHCO3), NaOH solution (aq. NaOH) and hydrochloric acid (aq. HC1), and then dried over MgSO4, filtered and evaporated in vacuo. Chromatographic separation was carried out on Merck Silica gel 60 using the indicated eluents.
Alkanoylacetonitriles and Aroylacetonitriles (154a-w) were prepared by means of the literature method.16) 2-Cyanoacetyl-2-cyclopentyl-1,3-dioxolane (154x)-Methyl methylsulfinylmethyl sulfide (FAMSO) (4.95 g, 39.9 mmol) was added dropwise to a mixture of tert-BuOK (8.95 g, 79.8 mmol) and tetrahydrofuran (THF) (45 ml) under cooling at 0 °C. After stirring of the mixture for 15 min, a solution of ethyl cyclopentylcarboxylate (67 g, 39.9 mmol) in THF (15 ml) was added dropwise. The reaction mixture was stirred at 20 °C for 14 h, and then cooled, quenched with aq. HC1, and extracted with CH2C12. The extract, after removal of the solvent, was chromatographed on silica gel with CH2C12-Et20 (1 : 1) to give cyclopentylcarbonyl-FAMSO (6.85 g, 78.0%) as a mixture of both isomers in the ratio of 4 : 6. 1H-NMR (CDC13) 6: 1.77 (8H, m), 2.15, 2.21 (3H, s), 2.62, 2.77 (3H, s), 3.22 (1H, m), 4.41, 4.52 (1H, s) . A mixture of the product (5.4 g, 24.5 mmol), CuC12.2H20 (5.03 g, 24.5 mmol) and EtOH (54 ml) was stirred for 21 h at 25 °C. The solvent was evaporated off, and the residue was extracted with benzene. After removal of the solvent, the extract was chromatographed on silica gel with hexane-ethyl acetate (EtOAc) (20 : 1) to give ethyl cyclopentylpyruvate (2.75g, 65.8%) as a colorless liquid. 1H-NMR (CDC13) 6: 1.83 (8H, m), 1.34 (3H, t, J= 7 Hz), 3.49 (1 H, m), 4.32 (2H, q, J =7 Hz). A solution of the pyruvate (1.58 g, 9.3 mmol), ethyleneglycol (0.7 g, 11.3 mmol) and boron trifluoride diethylether complex (44 ml) in benzene (6 ml) was stirred at 25 °C for 20 h. The mixture was quenched with aq. NaHCO3, washed with NaC1, dried over MgSO4, filtered, and evaporated. The residue was dissolved in MeCN (0.7 g, 17 mmol)-THF (8 ml), and the solution was added to a mixture of tert-BuOK (1.9 g, 17 mmol) and THF (10 ml) under cooling at 0 °C. The mixture, after stirring for 6 h at 25 'C, was quenched with aq. HC1, and extracted with benzene. Chromatography of the extract on silica gel with CH2C12 gave 154x (1.02 g, 60.1%) as a colorless liauid. 1H-NMR (CDChl 6: 1.56 (8H. ml. 2.37 (111 ml. 3.67 (2H. sl. 3.99 (4H. m).
5-Amino-1-methyl-3-R3-pyrazoles
(1-28)-1 (R3 = H),5) 2 (R3 = Me),6c) 3 (R3.-iso-Pr),6'2 4 (R3= Ph)," and 5 (R3 =2-pyridyl)6f) were prepared by the literature methods. The pyrazoles (6-28) were prepared by the following general procedure. A solution of 154 (20 mmol) and methylhydrazine (0.92 g, 20 mmol) in EtOH (15 ml Methyl 5-Amino-1-methylpyrazole-3-carboxylate (31) A solution of methyl cyanopyruvate sodium-enolate') (155, 10.0 g, 60 mmol) with methylhydrazine sulfate (9.0 g, 60 mmol) was stirred for 72 h at room temperature, and then evaporated. The residue was extracted with CHC13, and the extract was washed with aq. NaC1, dried over MgSO4, filtered, and evaporated. The residue was chromatographed on silica gel with EtOAc to give 31 (6.54 g, 70.3%). Recrystallization from EtOH gave colorless needles, mp 101-102 °C . 1H-NMR (CDC13) 6: 3.71 (3H, s), 3.90 (2H, br s), 3.86 (3H, s), 6.05 (1H, s).
iso-Propyl 5-Amino-1-methylpyrazole-3-carboxylate (32) A solution of 31 (2.0 g, 12.9 mmol) and iso-PrONa (0.1 g) in iso-PrOH (40 ml) was heated under reflux for 20 h. After removal of the solvent, the residue was extracted with CHC13, and the extract was washed with water, dried over MgSO4, filtered, and evaporated. The crystalline residue was recrystallized from iso-PrOH to give 32 (1.72 g, 72.9%) as colorless needles, mp 86-87 °C. 1H-NMR (CDC13) 6: 1.37 (6H, d, J=6 Hz), 3.72 (3H, s), 3.75 (2H, br s), 5.23 (1H, s). 5-Amino-3-cyclopentylcarbonyl-1-methylpyrazole ( 
5-Amino-1,3-diphenylpyrazole (29)
29 was prepared by a literature method.") 5-Amino-1,3-dicyclopentylpyrazole (30) A solution of cyclopentylcarbonylacetonitrile (154h, 0.69 g, 5 mmol) and cyclopentylhydrazine'" (0.5 g, 5 mmol) in EtOH (5 ml) was stirred for 16 h at 25 °C and then evaporated. The residue was chromatographed on silica gel with benzene-EtOAc (19: 1) to give 30 (0.79 g, 71.5%) as pale yellow crystals. Recrystallization from iso-Pr20-hexane gave colorless prisms, mp 92-93 °C. 111-NMR (CDC13 4.18, 4.43 (2H, t, J=7 Hz), 7.50 (9H, m) . 41 (R1= 3-trifluoromethylphenethyl): 54.1% yield. 11-I-NMR (CDC13) 6: 2. 10, 2.40 (3H, s), 2.77, 3.08 (2H, t, J=7 Hz), 4.23, 4.48 (2H, t, J=7 Hz), 7.68 (9H, m) . 42 (IV = 3,4dimethoxyphenethyl): 96.8% yield. 1 H-NMR (CDC13) 6: 2.08, 2.40 (3H, s), 2.62, 2.93 (2H, t, J= 7 Hz), 3.78, 3.83, 3.85 (6H, s), 4.18, 4.45 (2H, t, J=7 Hz), 7.16 (8H, m) . 43 (R1 = 3,5-dichlorophenethyl): 93.1% yield. 1 H-NMR (CDC13) 6: 2.12, 2.43 (3H, s), 2.67, 2.97 (2H, t, J= 7 Hz), 4.20, 4.45 (2H, t, J= 7 Hz), 7.49 (8H, m) . 44 (R1= cyclohexyl): 97.3% yield. 1 H-NMR (CDC13) 6: 1.50 (10H, m), 2.22, 2.47 (3H, s), 4.87 (1H, m), 7.78 (5H, m) . 45 (It' =2-methoxyethyl)m): 90.2% yield. 46 (It' =2-phenoxyethyl): 94.4% yield. H-NMR (CDC13) 6: 2.18, 2.42 (3H, s), 4.20 (4H, m), 7.42 (10H, m) . 47 [R1 =2-(4-chloro)phenethyl]: 95.2% yield. H-NMR (CDC13) 6: 2.17, 2.47 (3H, s), 4.23 (4H, m), 7.39 (9H, m) . 48 (IV = 3-isopropoxypropyl): 50.7% yield. '1-1-NMR (CDC13) 6: 1.08 (6H, d, J=6 Hz), 1.79 (2H, m), 2.47 (3H, s), 3.80 (5H, m), 7.76 (5H, m) . 49 (IV =2-cyclopentyloxyethyl): 84.0% yield. m), 2.23, 2.49 (3H, s), 3.82 (5H, m), 7.84 (5H, m) . 50 (IV =2-methylthioethyl): 86.7% yield. '1-1-NMR (CDC13) 6: 2.00, 2.17 (3H, s), 2.22, 2.48 (3H, s), 2.45, 2.83 (2H, t, J= 7 Hz), 4.17, 4.45 (2H, t, J= 7 Hz), 7.77 (5H, m) . 51 (IV = 2isopropylthioethyl): 93.2% yield. H-NMR (CDC13) 6: 1.20, 1.32 (6H, d, J=6 Hz), 2.23, 2.50 (3H, s), 2.51, 2.87 (2H, t, J=7 Hz), 2.97 (1H, m), 4.15, 4.42 (2H, t, J= 7 Hz), 7.78 (5H, m) . 52 (IV =2-cyclopentylthioethyl): 92.4% yield. NMR (CDC13) 6: 1.59 (8H, m), 2.23, 2.48 (3H, s), 2.52, 2.87 (2H, t, J= 7 Hz), 3.03 (1H, m), 4.17, 4.40 (2H, t, J= 7 Hz), 7.82 (5H, m Alkyl (12') 4-Ary1-1-R-3-R3-4,7-dihydro-6-methylpyrazolo-[3,4-b]pyridine-5-carboxylates (72-149) 72-149, prepared by the following general procedure, are listed in Tables I and II . A solution of a 5-aminopyrazole (1-33, 5 mmol) and an alkyl arylmethylideneacetoacetate (34-71, 5 mmol) in tert-BuOH (10 ml) was heated at 80 °C for 24 h under N2. After removal of the solvent, the residue was chromatographed on silica gel using benzene-EtOAc (2: 1) and EtOAc as the eluants. The benzene-EtOAc eluate was evaporated to obtain the Schiff base (151). The product from the EtOAc eluate was recrystallized from the indicated solvents to obtain the corresponding 4,7dihydropyrazolo[3,4-b]pyridine (72-149). When an oily product was obtained, it was converted into the hydrochloride or oxalate in the usual manner. The IR and 1H-NMR spectra of the products are shown in Table III . Methyl 4-(3-Aminophenyl)-3-cyclopenty1-4,7-dihydro-1,6-dimethylpyrazolo[3,4-b]pyridine-5-carboxylate (150) A solution of 76 (1.0 g, 2.52 mmol) in Me0H (10 ml) was hydrogenated in the presence of 10% Pd-C (0.1 g) under atmospheric pressure. After absorption of H2 (166 ml), the reaction was worked up, and the mixture was filtered and evaporated. The residue was chromatographed on silica gel with EtOAc and gave 150 (0.78 g, 84.1%). Recrystallization from EtOH gave colorless prisms, mp 106-110 °C (Table II) . IR (Nujol): 3430, 3300, 1690 cm'. 11-1 -NMR (CDC13) 6: 2 .02 (12H, m), 3.35 (2H, br s), 3.45 (3H, s), 3.55 (3H, s), 5.00 (114, s), 6.68 (4H, m), 7.58 (1H, br s).
Conversion of Methyl 3-Cyclopenty1-4,7-dihydro-6-methyl-4-phenylisoxazolo [5,4-b] pyridine- 5-carboxylate (158) into 149-A solution of 158" (2.67 g, 8.0 mmol) in EtOAc (25 ml) was hydrogenated over Pt02 (0.3 g) in H2 at room temperature for 6 h. The precipitated crystals were dissolved by addition of CH2C12. The solution, after removal of the catalyst by filtration, was evaporated and the residue was crystallized from EtOAc, giving 159 (2.5 g, 93.6%) as colorless prisms, mp 222-224 °C. IR (Nujol): 3450, 1695, 1605 cm'. 11-1-NMR (CDC13) 45: 1.53 (8H, m), 2.27 (3H, s), 3.09 (1H, m), 3.70 (3H, s), 4.98 (1H, s), 7.19 (5H, m). Anal. Calcd for C,,,1-12,N20,: C, 70.56; H, 7.11; N, 8.23. Found: C, 70.39; H, 7.00; N, 8.13 . POC13 (6 ml) was added dropwise to a solution of 159 (2.0 g, 6.84 mmol) in CH2C12 (6 ml) under cooling, and the solution was stirred at 25 °C for 20 h. After removal of the solvent, the residue was 
